SAVA has a new potential indication for simufilam, the treatment of seizures related to tuberous sclerosis complex, although the company is not yet running a clinical trial here. SAVA isn't done ...

Cassava Sciences SAVA recently suffered yet another setback, which raises concern regarding its prospects. Last week, the company announced that the phase III study REFOCUS-ALZ on lead pipeline ...

A downtrend has been apparent in Cassava Sciences, Inc. (SAVA) lately with too much selling pressure. The stock has declined 39.5% over the past four weeks. However, given the fact that it is now ...

Cassava Sciences (NASDAQ:SAVA) lost ~19% in the premarket on Tuesday after the company announced plans to discontinue its research program for its lead asset simufilam in Alzheimer’s disease by ...

Image Source: Zacks Investment Research Under its ... Based on the above study results, SAVA had discontinued the 76-week phase III REFOCUS-ALZ study and the open-label extension study on the ...

Among these, Cassava Sciences, Inc SAVA nosedived following the failure of a late-stage study, while Alnylam Pharmaceuticals ALNY gained following FDA nod for label expansion of its key drug.